AxoGen (AXGN)
(Real Time Quote from BATS)
$14.36 USD
+0.39 (2.79%)
Updated Sep 24, 2024 01:02 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXGN 14.36 +0.39(2.79%)
Will AXGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXGN
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
AXGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Alcon Stock in Your Portfolio for Now
Zacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGen
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
Other News for AXGN
AxoGen: An Intriguing Growth Story
Axogen Inc (AXGN) Shares Up 2.8% on Sep 17
ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc
AxoGen completes submission of BLA to U.S. FDA for Avance Nerve Graft
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft?